Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression (Q6629418)
From MaRDI portal
 | This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use this page instead for the normal view: Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression |
scientific article; zbMATH DE number 7935612
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression |
scientific article; zbMATH DE number 7935612 |
Statements
Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression (English)
0 references
30 October 2024
0 references
competing risks
0 references
dose-finding
0 references
oncology
0 references
phase I/II
0 references
survival data
0 references
0 references
0 references
